Stock fact sheet · data as of
Alpha Teknova, Inc. (TKNO): fair value, margin of safety and Wheel Score
Ticker symbol TKNO · Healthcare · Drug Manufacturers - Specialty & Generic · United States · Speculative
Is TKNO undervalued?
Alpha Teknova, Inc. (TKNO) closed at 7.37 on 5 Nov 2026. None of the nine GLS valuation models produced a positive value for the stock - the company lost money over the last twelve months, EPS -0.30, it pays no dividend and its debts exceed what its assets would fetch - so there is no GLS average fair value and no margin of safety to report. The quality, option and event numbers below still apply; the Quote page's Wall Street View shows what analysts expect instead.
The nightly engine files TKNO under Speculative - it is losing money or its Piotroski health score is 3 or lower - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for TKNO
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -0.0048 | -100% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 8.00 | +9% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: TKNO passes 4 of the nine Piotroski tests. Our scans drop the stock at the health filter; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.8 out of 10: returns on capital, margins or the balance sheet have not shown a lasting edge yet - often a young company, a thin-margin business or one that has only recently turned profitable.
Returns on capital are thin or negative - ROIC -20.6%, ROE -25.1%, ROA -16.7% - with debt at 0.22 times equity and negative free cash flow.
Alpha Teknova, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Lab Essentials 75%, Clinical Solutions 20%, Other Product 5% (quarter Q2 FY2026).
Institutional ownership scores 2/10, insider activity 10/10 and Congressional trading 1/10 on the GLS smart-money scales; the last recorded Congressional buy was on 10 Aug 2026.
| Piotroski F-score | 4 / 9 | ROIC | -20.6% |
|---|---|---|---|
| GLS Moat | 1.8 / 10 | ROE | -25.1% |
| Debt / equity | 0.22 | ROA | -16.7% |
| Free-cash-flow yield | -0.3% | Payout ratio | 0% |
| Institutions | 2 / 10 | Insiders · Congress | 10 · 1 / 10 |
Wheel Score 20: Weak
TKNO scores 20 out of 100 on the Wheel Score, in the Weak band (under 50): it fails filter 1, options that actually trade - options too quiet (941 open interest, 63 a day); and filter 2, a real business, not a gamble - speculative (a loss, or a weak Piotroski score); and filter 3, below fair value - trades right at our fair value; and filter 4, financially healthy - Piotroski 4/9 (under 6); and filter 5, can repay its debt - debt with no positive cash flow to repay it; and filter 7, a premium worth selling - implied volatility 97% (over 80%); and filter 8, big enough - market cap $455M (under $1.0B), and the parts are thin too - value weak, premium fair, moat weak, health fair, red flags good, option trading weak, stability fair. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.
Implied volatility is 97%, above the 80% ceiling of the Wheel Trade Filter on premium. The premium looks generous, but moves of that size can blow through any strike. Chain open interest is thin - 941 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.
Volume runs at 372k shares a day on a market cap of $455M, with a beta of 0.73 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | options too quiet (941 open interest, 63 a day) |
| 2 | A real business, not a gamble | Fails | speculative (a loss, or a weak Piotroski score) |
| 3 | Below fair value | Fails | trades right at our fair value |
| 4 | Financially healthy | Fails | Piotroski 4/9 (under 6) |
| 5 | Can repay its debt | Fails | debt with no positive cash flow to repay it |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Fails | implied volatility 97% (over 80%) |
| 8 | Big enough | Fails | market cap $455M (under $1.0B) |
| 9 | Not a penny stock | Passes | Share price $5 or more |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Weak | 0% below fair value | |
| Premium | Fair | implied volatility 97% | |
| Moat | Weak | moat 1.8/10 | |
| Health | Fair | Piotroski 4/9 | |
| Red Flags | Good | Red Flags score 85/100 | |
| Option trading | Weak | 63 contracts a day, 941 open interest | |
| Stability | Fair | beta 0.73, $455M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for TKNO in the nightly calendar.
No analyst upgrades or downgrades were recorded in the last 30 days.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Alpha Teknova, Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| AQST Aquestive Therapeutics, Inc. | 3.80 | - | - | 25Weak | $477M |
| KMDA Kamada Ltd. | 7.42 | 14.28 | +48% | 33Weak | $428M |
| EOLS Evolus, Inc. | 7.47 | 6.35 | -18% | 22Weak | $493M |
| VRNO Verano Holdings Corp | 5.16 | 27.65 | +81% | 30No options | $376M |
| EVO Evotec SE | 1.57 | - | - | 13No options | $558M |
| NIKA Nika Pharmaceuticals Inc. | 0.3500 | 0.0000 | -19409229% | 11No options | $367M |
| IRWD Ironwood Pharmaceuticals, Inc. | 3.77 | 12.30 | +69% | 36Weak | $623M |
| ACB Aurora Cannabis Inc. | 5.24 | - | - | 27Weak | $332M |
| TLRY Tilray Brands, Inc. | 2.96 | - | - | 24Weak | $331M |
| CGC Canopy Growth Corporation | 0.7517 | - | - | 11Weak | $318M |
| EBS Emergent BioSolutions Inc. | 5.90 | 45.07 | +87% | 36Weak | $303M |
| COLL Collegium Pharmaceutical, Inc. | 23.67 | 150.51 | +84% | 46Weak | $771M |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about TKNO
Is TKNO undervalued right now?
The GLS models could not value TKNO (the company lost money over the last twelve months, EPS -0.30, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 7.37 against.
What is the Wheel Score of TKNO and what does it mean?
TKNO scores 20 out of 100 (Weak) - it fails Wheel Trade Filters 1, 2, 3, 4, 5, 7, 8. The Wheel Score ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned - in two parts: the 9 pass/fail Wheel Trade Filters (busy options, a real business, below fair value, Piotroski 6 or more, debt it can repay, a Red Flags score of 60 or more, implied volatility of 25-80%, a $1 billion company, $5 a share) and a ranking of how strongly a stock passes on value, premium, moat, health, red flags, option trading and stability. A stock that fails any filter stays under 70; 70-84 is Good, 85 and above is Prime. The Sunday Scan is the top 10 that pass, sorted by Wheel Score.
What is the GLS fair value for TKNO?
None of the nine GLS models produced a positive value for TKNO (the company lost money over the last twelve months, EPS -0.30, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.
When does Alpha Teknova, Inc. report earnings next?
No upcoming earnings date is recorded for TKNO in our calendar as of 5 Nov 2026; the Calendars page is refreshed every morning.
Does TKNO have listed options, and how liquid are they?
Yes. The nightly snapshot found 12 listed contracts with 941 open interest across all expiries and implied volatility of 97% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.